Latest Articles
Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer - CUREtoday.com
Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer CUREtoday.com
Published: Oct. 19, 2025, 6:39 p.m.
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - CancerNetwork
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer CancerNetwork
Published: Oct. 19, 2025, 4:40 p.m.
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - cancernetwork.com
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer cancernetwork.com
Published: Oct. 19, 2025, 4:40 p.m.
Ibuprofen: How an everyday drug might offer protection against cancer - Medical Xpress
Ibuprofen: How an everyday drug might offer protection against cancer Medical Xpress
Published: Oct. 19, 2025, 4:30 p.m.
Dominique Dagenais Cedars Run for ovarian cancer marks a decade and honours its late founder in Montreal - CityNews Montreal
Dominique Dagenais Cedars Run for ovarian cancer marks a decade and honours its late founder in Montreal CityNews Montreal
Published: Oct. 19, 2025, 3:21 p.m.
Exclusive: Sid Mukherjee’s Faeth nets $25M for endometrial cancer study - Endpoints News
Exclusive: Sid Mukherjee’s Faeth nets $25M for endometrial cancer study Endpoints News
Published: Oct. 19, 2025, 9:01 a.m.
Giorgio Bogani: New Insights into POLE-Mutated Endometrial Cancer with Nodal Involvement - Oncodaily
Giorgio Bogani: New Insights into POLE-Mutated Endometrial Cancer with Nodal Involvement Oncodaily
Published: Oct. 18, 2025, 10:08 p.m.
Victoria’s Secret Spotlight: Dylan Sprouse and Barbara Palvin Champion Women’s Health and Precancer Diseases Awareness - Oncodaily
Victoria’s Secret Spotlight: Dylan Sprouse and Barbara Palvin Champion Women’s Health and Precancer Diseases Awareness Oncodaily
Published: Oct. 18, 2025, 9:25 p.m.
The cancer that won’t stop rising - ThePost.co.nz
The cancer that won’t stop rising ThePost.co.nz
Published: Oct. 18, 2025, 4 p.m.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Lelezard
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Lelezard
Published: Oct. 18, 2025, 12:47 p.m.
Link copied to clipboard!